CYTK

66.60

1.05% 0.69

시간 외 거래: 66.61 0.01 +0.02%

Cytokinetics Inc (CYTK)

개요 뉴스 가격 이력 옵션 체인 Financials CYTK 왜 하락? 토론 예측 주식 분할

전일 마감가:

$65.91

열려 있는:

$66.55

하루 거래량:

2.14M

Relative Volume:

1.12

시가총액:

$8.20B

수익:

$88.04M

순이익/손실:

$-784.96M

주가수익비율:

-10.19

EPS:

-6.5335

순현금흐름:

$-534.82M

1주 성능:

+6.75%

1개월 성능:

+7.04%

6개월 성능:

+19.27%

1년 성능:

+77.60%

1일 변동 폭

$65.95

$67.92

1주일 범위

$61.67

$67.92

52주 변동 폭

$29.31

$70.98

Cytokinetics Inc Stock (CYTK) Company Profile

명칭

Cytokinetics Inc

부문

Healthcare (1115)

산업

Biotechnology (623)

전화

(650) 624-3000

주소

350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA

직원

673

트위터

@Cytokinetics

다음 수익 날짜

2026-02-24

최신 SEC 제출 서류

CYTK's Discussions on Twitter

Compare CYTK vs VRTX, REGN, ARGX, ALNY, INSM

주식	가격	시가총액	매출	순이익	현금흐름	주당 순 이익
CYTK Cytokinetics Inc	66.60	8.12B	88.04M	-784.96M	-534.82M	-6.5335
VRTX Vertex Pharmaceuticals Inc	447.26	113.44B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	777.25	81.68B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	743.12	45.32B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	328.73	43.88B	3.71B	313.75M	465.38M	2.2571
INSM Insmed Inc	165.01	35.25B	606.42M	-1.28B	-997.58M	-6.403

Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades

날짜	액션	분석자	등급 변경
2026-01-28	재개	Barclays	Overweight
2025-12-18	업그레이드	Goldman	Neutral → Buy
2025-07-30	재개	Raymond James	Mkt Perform
2025-04-24	개시	Barclays	Overweight
2025-02-07	개시	Citigroup	Buy
2025-01-22	개시	Stifel	Buy
2024-11-08	개시	RBC Capital Mkts	Outperform
2024-08-13	다운그레이드	Goldman	Buy → Neutral
2024-01-24	다운그레이드	UBS	Buy → Neutral
2024-01-05	다운그레이드	Morgan Stanley	Overweight → Equal-Weight
2023-11-09	개시	Goldman	Buy
2023-11-07	개시	B. Riley Securities	Buy
2023-08-15	개시	SVB Securities	Outperform
2023-02-17	개시	BofA Securities	Neutral
2022-12-23	재확인	Needham	Buy
2022-12-20	개시	Truist	Buy
2022-10-11	개시	UBS	Buy
2022-01-28	개시	Goldman	Buy
2021-12-22	개시	Oppenheimer	Outperform
2021-12-10	개시	JP Morgan	Overweight
2021-10-07	개시	Jefferies	Buy
2021-03-12	개시	Wolfe Research	Outperform
2021-02-18	개시	Barclays	Overweight
2021-01-20	재확인	H.C. Wainwright	Buy
2020-10-29	개시	Goldman	Neutral
2020-07-10	개시	Raymond James	Strong Buy
2020-05-05	개시	Mizuho	Buy
2020-04-09	업그레이드	Morgan Stanley	Equal-Weight → Overweight
2018-09-21	개시	Cantor Fitzgerald	Overweight
2018-09-10	재개	Morgan Stanley	Equal-Weight
2017-11-22	재확인	Morgan Stanley	Overweight
2017-11-22	다운그레이드	Needham	Strong Buy → Buy
2017-11-21	재확인	H.C. Wainwright	Buy
2017-07-31	개시	Morgan Stanley	Overweight
2017-03-08	개시	Rodman & Renshaw	Buy
2017-02-06	업그레이드	Needham	Buy → Strong Buy
2016-12-16	개시	Cantor Fitzgerald	Overweight
2016-07-28	재확인	Needham	Buy
2015-11-10	재확인	FBR Capital	Outperform
2015-11-09	재확인	ROTH Capital	Buy
2015-07-24	재확인	MLV & Co	Buy
2014-12-31	재확인	ROTH Capital	Buy
2014-11-04	업그레이드	MLV & Co	Hold → Buy
2014-04-28	재확인	Needham	Buy

모두보기

Cytokinetics Inc 주식(CYTK)의 최신 뉴스

06:36 AM

CYTK Stock News Today | Earnings, Events & Price Alerts - Intellectia AI

06:36 AM

01:58 AM

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Cytokinetics, Incorporated (CYTK) And Encourages Shareholders to Reach Out - ACCESS Newswire

01:58 AM

Mar 31, 2026

Insider Sell: Andrew Callos Sells Shares of Cytokinetics Inc (CYTK) - GuruFocus

Mar 31, 2026

Callos, Cytokinetics EVP, sells $236k in shares - Investing.com

Mar 31, 2026

3,639 RSUs registered; CYTK (NASDAQ: CYTK) insider 10b5-1 sales listed - Stock Titan

Mar 31, 2026

Cytokinetics (CYTK) EVP sells 3,639 shares, retains 66,004 - Stock Titan

Mar 31, 2026

Mar 30, 2026

Retail Trends: Is Cytokinetics Incorporated trading at a discount2026 Summary & Low Risk Entry Point Guides - baoquankhu1.vn

Mar 30, 2026

Truist Financial Maintains Cytokinetics(CYTK.US) With Buy Rating - 富途牛牛

Mar 30, 2026

Why is Cytokinetics (CYTK) down 0.8% since last earnings report? - MSN

Mar 30, 2026

Mar 29, 2026

Cytokinetics Inc (HAM:KK3A) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus

Mar 29, 2026

Aug Drivers: What are the future prospects of Cytokinetics Incorporated2026 Macro Impact & Verified Entry Point Detection - baoquankhu1.vn

Mar 29, 2026

Mar 28, 2026

Cytokinetics (CYTK) Reports Q2 Loss, Tops Revenue Estimates - MSN

Mar 28, 2026

Cytokinetics, Incorporated (NASDAQ:CYTK) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat

Mar 28, 2026

Cytokinetics Inc Stock Intrinsic Values | HAM:KK3A - GuruFocus

Mar 28, 2026

Cytokinetics Inc (HAM:KK3A) Competitors 2026 - GuruFocus

Mar 28, 2026

Mar 27, 2026

Should you avoid Cytokinetics Incorporated stock right nowQuarterly Risk Review & Fast Entry and Exit Trade Plans - baoquankhu1.vn

Mar 27, 2026

Mar 26, 2026

Vanguard disaggregates holdings; CYTK filings now split among subsidiaries (CYTK) - Stock Titan

Mar 26, 2026

Cytokinetics Inc (HAM:KK3A) Dividend - GuruFocus

Mar 26, 2026

Cytokinetics, Incorporated (CYTK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

Mar 26, 2026

Why Is Cytokinetics (CYTK) Down 0.8% Since Last Earnings Report? - Yahoo Finance

Mar 26, 2026

Cytokinetics Inc at Barclays Global Healthcare Conference Transcript - GuruFocus

Mar 26, 2026

Spinal Muscular Atrophy Pipeline 2026: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Genentech, Chugai Pharma, Cytokinetics, Ionis Pharma, Genzyme Corp - Barchart.com

Mar 26, 2026

Cytokinetics Inc (HAM:KK3A) Stock HoldersInstitutional & Insider Ownership - GuruFocus

Mar 26, 2026

Mar 25, 2026

Aug Catalysts: What is the long term forecast for Cytokinetics Incorporated stockShort Setup & High Accuracy Trade Alerts - baoquankhu1.vn

Mar 25, 2026

Mar 24, 2026

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Cytokinetics, Incorporated (CYTK) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire

Mar 24, 2026

E. Ohman J or Asset Management AB Has $23.06 Million Stock Holdings in Cytokinetics, Incorporated $CYTK - MarketBeat

Mar 24, 2026

Mar 23, 2026

Biohaven Stock Down 70% but One Fund's New $6 Million Bet Signals Turnaround Potential - The Motley Fool

Mar 23, 2026

Cytokinetics, Incorporated (CYTK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

Mar 23, 2026

Mar 22, 2026

2026-03-22 | Cytokinetics, Incorporated (CYTK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:CYTK | Press Release - Stockhouse

Mar 22, 2026

Mar 20, 2026

Cytokinetics, Incorporated $CYTK Shares Bought by Hudson Bay Capital Management LP - MarketBeat

Mar 20, 2026

Mar 19, 2026

Cytokinetics (CYTK) EVP sells 1,930 shares, retaining over 78,000 - Stock Titan

Mar 19, 2026

Bronstein, Gewirtz & Grossman, LLC Is Investigating Cytokinetics, Incorporated (CYTK) And Encourages Investors to Connect - ACCESS Newswire

Mar 19, 2026

Mar 18, 2026

Insider Sell: Andrew Callos Sells Shares of Cytokinetics Inc (CY - GuruFocus

Mar 18, 2026

Sung Lee Sells 4,935 Shares of Cytokinetics (NASDAQ:CYTK) Stock - MarketBeat

Mar 18, 2026

Insider Selling: Cytokinetics (NASDAQ:CYTK) EVP Sells 1,930 Shares of Stock - MarketBeat

Mar 18, 2026

Malik Fady Ibraham sells Cytokinetics (CYTK) stock worth $747,850 By Investing.com - Investing.com Canada

Mar 18, 2026

Blum, Cytokinetics CEO, sells $2.2m in shares By Investing.com - Investing.com Canada

Mar 18, 2026

Insider Selling: Cytokinetics (NASDAQ:CYTK) CEO Sells 36,601 Shares of Stock - MarketBeat

Mar 18, 2026

Fady Ibraham Malik Sells 12,033 Shares of Cytokinetics (NASDAQ:CYTK) Stock - MarketBeat

Mar 18, 2026

Andrew Callos Sells 8,542 Shares of Cytokinetics (NASDAQ:CYTK) Stock - MarketBeat

Mar 18, 2026

Malik Fady Ibraham sells Cytokinetics (CYTK) stock worth $747,850 - Investing.com

Mar 18, 2026

Cytokinetics Insiders Sold Shares Worth Over $3.6M - TradingView

Mar 18, 2026

Cytokinetics (CYTK) CFO share sale covers RSU tax obligations - Stock Titan

Mar 18, 2026

Mizuho Raises Price Target for Cytokinetics (CYTK) to $100 | CYT - GuruFocus

Mar 18, 2026

Cytokinetics (CYTK) EVP executes 8,542-share sell-to-cover for RSU taxes - Stock Titan

Mar 18, 2026

[Form 4] CYTOKINETICS INC Insider Trading Activity - Stock Titan

Mar 18, 2026

Cytokinetics President & CEO Sold Shares Worth Over $2.2M - TradingView

Mar 18, 2026

Cytokinetics (CYTK) CEO executes sell-to-cover stock sales for taxes - Stock Titan

Mar 18, 2026